United States Drug Patent 4,529,601: Claim Scope, Expiration, and Patent Landscape for the Lidocaine-Prilocaine Eutectic Mixture

U.S. Patent No. 4,529,601 protects a eutectic local-anesthetic composition combining prilocaine base and lidocaine base in specified weight ratios to produce a homogeneous oil with a melting point below 40°C, preferably below 25°C. The patent also covers topical or parenteral use of the combination. It issued on July 16, 1985, and its ordinary 17-year term expired on July 16, 2002. The patent therefore has no current blocking effect in the United States. Its commercial importance is historical because the claimed composition corresponds to the active anesthetic system used in EMLA cream.

What invention does U.S. Patent 4,529,601 cover?

The patent covers a physical mixture of two local anesthetic bases:

Prilocaine base
Lidocaine base

The claimed ratio range is 42:58 to 80:20, expressed as prilocaine-to-lidocaine by weight. The mixture must form a homogeneous oil with a melting point below 40°C.

The central technical concept is a eutectic or near-eutectic mixture. Pure prilocaine and pure lidocaine are solids at ordinary handling temperatures. When combined within the claimed range, their melting behavior changes, producing an oil or liquid mixture that can be incorporated into topical formulations and applied without first converting both anesthetics into conventional water-soluble salts.

The claims are directed to the combination and its physical properties rather than to either anesthetic individually. The patent does not broadly claim lidocaine, prilocaine, all local-anesthetic mixtures, or every topical anesthetic cream.

What are the key patent details and expiration dates?

Item	Detail
Patent	U.S. Patent No. 4,529,601
Title	Local anesthetic composition
Patent type	Composition of matter and method of use
Issue date	July 16, 1985
Patent term applicable to the patent	17 years from issuance
Ordinary expiration date	July 16, 2002
Core active ingredients	Prilocaine base and lidocaine base
Principal commercial association	EMLA topical anesthetic system
Current enforceability	Expired
Current Paragraph IV exposure under this patent	None

The patent predates the 20-year-from-earliest-effective-filing-date term introduced by the Uruguay Round Agreements Act. For this patent, the relevant ordinary term was 17 years from issuance under the law applicable to pre-1995 patents. No current patent term extension or pediatric exclusivity can revive the expired patent under the Hatch-Waxman framework.

The expiration date is therefore a historical date, not a current market barrier. [1]

How broad is claim 1?

Claim 1 is the principal composition claim. It requires all of the following limitations:

A locally active anesthetic agent.
A homogeneous oil.
Suitability for topical or parenteral administration.
Prilocaine in base form.
Lidocaine in base form.
A prilocaine-to-lidocaine weight ratio from 42:58 to 80:20.
A resulting melting point below 40°C.
A formulation consisting essentially of the two bases, subject to the legal meaning of that phrase.

A composition outside any required limitation would fall outside the literal scope of claim 1. Examples include:

A mixture containing lidocaine hydrochloride instead of lidocaine base.
A mixture containing prilocaine hydrochloride instead of prilocaine base.
A ratio outside the 42:58 to 80:20 range.
A composition that is not a homogeneous oil.
A composition with a melting point of 40°C or higher.
A formulation in which additional ingredients materially alter the claimed anesthetic composition.

The claim is narrower than a claim to the finished cream. It is directed to the anesthetic mixture and its physical state. A finished dosage form could implicate the claim if the product contains the claimed mixture, even if the product also contains water, emulsifiers, stabilizers, preservatives, or other excipients. That analysis would depend on the meaning of “consisting essentially of” and whether the added components materially change the basic and novel characteristics of the claimed mixture.

What do claims 2 through 6 add?

Claims 2 through 6 narrow the composition by tightening the melting-point, ratio, or formulation limitations.

Claim	Limitation
1	Ratio 42:58 to 80:20; homogeneous oil; melting point below 40°C
2	Melting point below 25°C
3	Ratio narrowed to 47:53 to 62:38
4	Ratio fixed at 55:45
5	Ratio fixed at 52:48
6	Ratio fixed at 50:50 and includes an emulsifying agent

Claim 2 is a narrower physical-property claim. A mixture that melts at 25°C or above could remain within claim 1 but would fall outside claim 2.

Claim 3 removes the outer portions of the broad ratio range. Claims 4 and 5 protect specific ratios within that narrower range. Claim 6 is directed to a 50:50 mixture that also contains an emulsifier, which is particularly relevant to cream formulations.

The dependent claims create fallback positions around the expected commercial formulation. They also reduce the risk that invalidity of the broadest ratio range would eliminate every narrower claim.

What do claims 7 through 11 protect?

Claims 7 through 11 are method-of-use claims. They cover obtaining local anesthesia in mammals by topical or parenteral administration of the claimed prilocaine-base/lidocaine-base mixture.

The method claims reproduce the composition limitations found in claims 1 through 6:

Claim 7 covers the broad 42:58 to 80:20 range and melting point below 40°C.
Claim 8 narrows the ratio to 47:53 to 62:38.
Claim 9 specifies 55:45.
Claim 10 specifies 52:48.
Claim 11 specifies 50:50 with an emulsifying agent.

The method claims require administration of an “anesthetically effective amount.” They do not claim every use of lidocaine or prilocaine. They require the claimed combination, in base form and within the specified physical and compositional limits, to be administered to a mammal for local anesthesia.

The word “parenteral” broadens the route language beyond topical application, but it does not remove the mixture, ratio, oil, and melting-point requirements.

What formulation does the patent protect?

The patent is closely associated with the eutectic anesthetic mixture used in EMLA cream. The marketed EMLA formulation contains lidocaine 2.5% and prilocaine 2.5%, corresponding to a 50:50 ratio of the two active ingredients by weight in the finished cream. The product also contains an emulsifying system and other excipients. [2]

The patent’s formulation relevance is strongest for a product that contains:

Lidocaine base and prilocaine base.
A 50:50 active-to-active ratio.
A homogeneous eutectic mixture.
A melting point below 25°C.
An emulsified cream or related topical dosage form.

The patent does not require a particular cream base, concentration in the finished product, package, application device, occlusive dressing, treatment duration, or indication such as venipuncture, vaccination, tattooing, or dermatologic procedures.

A formulation containing the same active ingredients as separate particles, separate salt forms, or a non-eutectic physical arrangement would require a different infringement analysis. The claim language focuses on the mixture’s physical state and melting behavior, not merely on the presence of both active ingredients.

What is the scope of the “consisting essentially of” language?

“Consisting essentially of” is an intermediate transition between “comprising” and “consisting of.” It generally permits additional components that do not materially affect the basic and novel characteristics of the claimed composition.

For this patent, the basic and novel characteristics are likely to include:

The combination of prilocaine base and lidocaine base.
The specified ratio.
Formation of a homogeneous oil.
Depression of the melting point below the stated threshold.
Use as a local anesthetic.

An excipient such as an emulsifier, preservative, water, thickener, or stabilizer may not automatically remove a product from the claim. Claim 6 expressly contemplates an emulsifying agent in the 50:50 embodiment. That language supports the view that at least some additional formulation ingredients are compatible with the claimed invention.

By contrast, an added component that prevents formation of the eutectic oil, changes the anesthetic system’s essential physical behavior, or creates a materially different active composition could support a noninfringement position. The issue would turn on claim construction and evidence concerning the composition’s physical and functional characteristics.

What is the patent’s Orange Book status?

U.S. Patent No. 4,529,601 is expired and does not provide current Orange Book protection for EMLA or a generic lidocaine-prilocaine product.

The Orange Book lists patents and regulatory exclusivities associated with approved drug products, but an expired patent cannot block approval or launch. Current regulatory analysis must be performed against the active patents listed for the relevant reference-listed drug, if any, rather than against U.S. Patent No. 4,529,601. [3]

For generic lidocaine-prilocaine cream, the patent’s expiration means:

The patent cannot support a current Paragraph IV certification.
A generic applicant does not need to wait for this patent to expire.
A Paragraph IV notice based solely on this patent would have no practical blocking effect.
The patent cannot create a 30-month stay under the Hatch-Waxman Act.
Any present launch risk must arise from later patents, regulatory exclusivity, product-specific labeling, or nonpatent barriers.

Did the patent create Paragraph IV litigation risk?

During its term, the patent could have been relevant to an abbreviated new drug application for a product containing the same eutectic lidocaine-prilocaine system. A generic applicant could have addressed the patent through a Paragraph IV certification alleging invalidity, unenforceability, or noninfringement, or through a Paragraph III certification before the patent’s expiration.

After July 16, 2002, the patent ceased to create a meaningful Paragraph IV barrier. The current statutory framework does not allow an expired patent to generate the litigation stay associated with a valid, unexpired Orange Book patent. [4]

No current generic launch strategy should treat U.S. Patent No. 4,529,601 as an enforceable patent risk.

What patent litigation and settlement issues affect the patent?

The patent’s term has expired, so any historical infringement litigation under the patent would no longer create prospective exclusionary rights. A settlement that delayed generic entry beyond July 16, 2002 would also have no continuing effect unless it contained separate contractual restrictions, which would require analysis of the agreement itself.

The principal present litigation questions are different:

Whether later patents cover a specific cream vehicle.
Whether later patents cover a delivery system or applicator.
Whether a generic label induces use of a patented indication.
Whether trade dress, trademark, or regulatory exclusivity affects market entry.
Whether manufacturing claims cover a particular process or impurity profile.

Those rights are distinct from the expired composition and method claims in U.S. Patent No. 4,529,601.

How strong was the patent estate?

The patent was technically important but structurally narrow in several respects.

Strength	Limitation
Claims a defined eutectic anesthetic system	Requires both active ingredients in base form
Covers broad ratio range of 42:58 to 80:20	Requires a homogeneous oil
Covers melting point below 40°C	Physical-property proof may be product-specific
Includes topical and parenteral use	Does not cover all lidocaine-prilocaine products
Includes specific 50:50 emulsified embodiment	Patent term expired in 2002

The strongest historical claim was likely the combination of claims 1, 2, and 6 as applied to a 50:50 lidocaine-prilocaine eutectic incorporated into an emulsion. The broadest claim, claim 1, had wider ratio coverage but remained subject to the homogeneous-oil and sub-40°C melting-point limitations.

The patent’s current strength is zero as an enforceable U.S. exclusion right because the patent has expired. Its remaining value is prior-art, technology-history, and freedom-to-operate context.

How does U.S. Patent 4,529,601 compare with current generic products?

The commercial product category includes branded EMLA and generic lidocaine-prilocaine creams. The relevant competitive distinction is no longer ownership of the original eutectic patent. It is the ability to obtain FDA approval, match the reference product’s quality attributes, and compete on price, distribution, packaging, and institutional contracts.

Issue	EMLA	Generic lidocaine-prilocaine cream
Active ingredients	Lidocaine and prilocaine	Lidocaine and prilocaine
Typical active ratio	50:50	Generally designed to match the reference product
Dosage form	Topical cream	Topical cream
Original eutectic patent	U.S. 4,529,601	Expired and not blocking
FDA pathway	NDA	ANDA or applicable abbreviated pathway
Current patent risk from U.S. 4,529,601	None	None
Main competitive issues	Brand recognition and distribution	Price, supply, approval, and product quality

The existence of the expired patent does not establish that every current generic formulation is identical to EMLA. It establishes that the core eutectic concept is in the public domain.

What generic launch risks remain?

The original patent creates no generic launch risk. Remaining risks may arise from:

Regulatory approval. The applicant must demonstrate pharmaceutical equivalence, bioequivalence or applicable product comparability, manufacturing quality, and labeling compliance.
Later patents. Later patents may claim vehicles, delivery systems, packaging, manufacturing methods, or narrower uses.
Manufacturing controls. Lidocaine-prilocaine products require control of homogeneity, phase behavior, assay, degradation, microbial quality, and preservative performance.
Supply chain execution. Cream products can face manufacturing and component-sourcing constraints even when patent barriers are absent.
Labeling. A generic label that encourages a patented method could create a separate induced-infringement issue if a relevant unexpired method patent exists.
Commercial substitution. Hospital and retail formularies may control uptake more than patent status.

No biosimilar analysis applies to this product. Lidocaine and prilocaine are small-molecule active ingredients, and generic competition proceeds through small-molecule drug pathways rather than the biosimilar provisions of the Public Health Service Act.

What is the geographic coverage of the patent estate?

U.S. Patent No. 4,529,601 provided protection only in the United States. Foreign counterpart patents, if granted, had separate terms, claim sets, and expiration dates. The U.S. expiration date cannot be applied automatically to Canada, Europe, Japan, or other jurisdictions.

For current international freedom-to-operate analysis, the relevant questions are:

Whether a counterpart patent was granted in the target country.
Whether it expired, lapsed, or was abandoned.
Whether a later national patent covers the formulation or manufacturing process.
Whether national regulatory exclusivity remains.
Whether the commercial product is imported, locally manufactured, or supplied through a license.

The U.S. patent itself creates no current restriction on manufacture, sale, or use outside the United States.

Key Takeaways

U.S. Patent No. 4,529,601 covers a homogeneous eutectic oil containing prilocaine base and lidocaine base.
The broad ratio is 42:58 to 80:20, with a melting point below 40°C.
Narrower claims cover melting point below 25°C, ratios from 47:53 to 62:38, specific 55:45, 52:48, and 50:50 embodiments, including emulsified formulations.
Claims 7 through 11 cover topical or parenteral administration for local anesthesia.
The patent issued on July 16, 1985, and expired on July 16, 2002.
It has no current Orange Book blocking effect and cannot support a current Paragraph IV stay.
The patent is historically associated with the EMLA lidocaine-prilocaine cream system.
Current competition depends on FDA approval, later patent rights, manufacturing capability, supply, labeling, and commercial access.
No biosimilar pathway applies because lidocaine and prilocaine are small-molecule drugs.

FAQs

Does U.S. Patent 4,529,601 cover EMLA cream?

It covers the underlying lidocaine-base/prilocaine-base eutectic anesthetic system associated with EMLA. It does not claim every aspect of the marketed cream, including all excipients, packaging, labeling, or delivery systems.

Can a generic company launch a lidocaine-prilocaine cream despite this patent?

Yes. The patent expired on July 16, 2002. It cannot block a current generic launch or create a current Paragraph IV stay.

Does the patent cover lidocaine or prilocaine salts?

No. The claims specifically require lidocaine and prilocaine in base form. Salt-based formulations require separate analysis.

Is a 50:50 lidocaine-prilocaine mixture within the patent claims?

Yes, if it also satisfies the required physical limitations, including formation of a homogeneous oil and the applicable melting-point limitation. Claim 6 specifically addresses a 50:50 mixture containing an emulsifying agent.

Does the patent cover injectable lidocaine-prilocaine products?

The method claims recite topical or parenteral application, but the administered combination must still satisfy the claimed base-form, ratio, homogeneous-oil, and melting-point requirements. The patent does not cover every injectable product containing lidocaine or prilocaine.

References

United States Patent and Trademark Office. (1985). U.S. Patent No. 4,529,601, Local anesthetic composition. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). EMLA cream prescribing information: Lidocaine 2.5% and prilocaine 2.5%. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). ANDA submissions: Patent certification and related provisions under the Federal Food, Drug, and Cosmetic Act. FDA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	7713618	Dec 01, 1977

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	218948	⤷ Start Trial
Austria	364451	⤷ Start Trial
Austria	A859578	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,529,601

Summary for Patent: 4,529,601